{"product_id":"sdgr-bcg-matrix","title":"(SDGR) Schrödinger, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Schrödinger, Inc. BCG Matrix is a company-specific strategic tool used to assess the business’s products or units across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysics-based software platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSchrödinger’s physics-based platform is the core Star: it uses molecular simulation and physics-based modeling to speed drug and materials discovery, and it serves pharma and materials customers worldwide. This is the main growth engine, with the business reporting 2024 revenue of about $211 million, led by platform demand. High share and high growth make it the clearest Star in the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiveDesign collaboration platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiveDesign is a Star in Schrödinger, Inc.'s BCG Matrix because it powers collaborative medicinal-chemistry work and fits the shift to cloud-based, multiuser discovery tools. As pharma teams standardize on shared workflows, LiveDesign helps Schrödinger deepen accounts and expand usage across users and programs. That stickier use case should support recurring software revenue and higher wallet share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFEP+ lead-optimization engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFEP+ sits in the Star quadrant: it is Schrödinger, Inc.’s best-known binding-affinity model and uses physics-based free-energy calculations to improve lead optimization hit rates. With computational drug-discovery spending rising fast, and AI-in-drug-discovery markets forecast to grow at 30%+ CAGR, FEP+ stays well placed for continued adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMaterials science software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSchrödinger, Inc.'s materials science software is a Star because it serves a fast-growing market where customers use simulation to cut lab work, lower experiment spend, and shorten design cycles. It also widens Schrödinger, Inc.'s reach beyond life sciences into chemicals, batteries, and advanced materials, which improves the size of the addressable market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrives broader non-biotech demand\u003c\/li\u003e\n\u003cli\u003eBenefits from lower R\u0026amp;D cycle time\u003c\/li\u003e\n\u003cli\u003eSupports expansion into chemicals\u003c\/li\u003e\n\u003cli\u003eStrengthens software-led revenue mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntegrated AI plus physics workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntegrated AI plus physics workflows are still a growth leg for Schrödinger, Inc., but they ride on a proven software base, which lowers adoption risk. The mix is attractive because AI can speed hit finding while physics-based simulation keeps results credible; the opportunity scales if more pharma customers move from pilots to repeat use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eExpansion stage, not core maturity\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAI adds speed; physics adds trust\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eUpside depends on customer conversion\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSchrödinger’s Star Assets: High Growth, High Stickiness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSchrödinger’s Star assets are its physics-based platform, LiveDesign, FEP+, and materials science software, which together drive the company’s growth engine. In 2024, revenue was about $211 million, showing the platform’s scale and market pull. These tools stay in the Star quadrant because they combine high growth with strong customer stickiness.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003e$211M 2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiveDesign\u003c\/td\u003e\n\u003ctd\u003eCollab workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFEP+\u003c\/td\u003e\n\u003ctd\u003eLead-optimization edge\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eSchrödinger, Inc. BCG Matrix: maps software and drug-discovery units across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix snapshot for Schrödinger, Inc. to pinpoint growth, cash cows, and drag fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Schrödinger, Inc., helping users verify key claims fast and make better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSoftware maintenance renewals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSoftware maintenance renewals are Schrödinger, Inc.'s cash cow because the installed base keeps paying to support core modeling workflows. In 2024, software revenue remained the company’s main recurring engine, helping fund R\u0026amp;D while adding little incremental selling cost. That makes renewals a steady, high-margin cash source even when new logo growth slows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnterprise subscription contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnterprise subscription contracts give Schrödinger, Inc. steady recurring revenue because large pharma clients often renew multiyear access deals. That improves backlog visibility and lowers churn risk, which fits BCG \"cash cow\" behavior in a mature account base. In a 2025-style renewal pool, these contracts usually matter more for cash flow stability than for fast growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and government licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSchrödinger’s academic and government licenses are a steady cash cow: universities and public labs buy them at slower growth rates, but they keep the Company in front of future industry users. These accounts usually need less promotional spend than large enterprise wins, so they support margin discipline. The broad installed base also helps Schrödinger stay embedded across discovery workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTraining and support services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTraining and support services act as a cash cow for Schrödinger, Inc. once its software is deployed, because implementation, onboarding, and technical support turn into recurring, lower-cost service work. This support layer lifts margins on the installed base without heavy growth capex, so it helps fund R\u0026amp;D and sales while keeping operating leverage strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue after deployment\u003c\/li\u003e\n\u003cli\u003eLow capital needs, higher margins\u003c\/li\u003e\n\u003cli\u003eSupports embedded software retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLegacy software modules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s legacy software modules fit the Cash Cow box because older, widely adopted tools can keep earning from long-tenured customers even when growth slows. In 2025 filings, the company still showed recurring software revenue tied to its installed base, so these modules help fund R\u0026amp;D and newer product bets without needing heavy reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable installed-base monetization\u003c\/li\u003e\n\u003cli\u003eLow growth, high margin profile\u003c\/li\u003e\n\u003cli\u003eSupports company cash generation\u003c\/li\u003e\n\u003cli\u003eFunds newer product development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSchrödinger’s Steady Cash Engines Keep Funding Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s cash cows are its installed-base software renewals, enterprise subscriptions, academic and government licenses, and support services. These lines are mature, low-capex, and recurring, so they keep cash flowing while the Company funds R\u0026amp;D. Legacy modules also stay profitable even when new logo growth slows.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewals\u003c\/td\u003e\n\u003ctd\u003eRecurring, high-margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions\u003c\/td\u003e\n\u003ctd\u003eMulti-year cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport\u003c\/td\u003e\n\u003ctd\u003eLow-cost service revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eSchrödinger, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Schrödinger, Inc. BCG Matrix you’re previewing is the exact same document you’ll receive after purchase. No sample pages, no watermarks—just the full, professionally formatted report ready for immediate use. Download it once purchased and use it for analysis, presentations, or strategic planning right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiscontinued drug candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc. has 0 marketed drugs, so discontinued drug candidates add no ongoing sales and little future value. They mainly reflect sunk R\u0026amp;D spend, not growth, and fit the BCG \"dog\" bucket. In FY2025, that kept capital tied to past programs instead of new winners.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerminated collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerminated collaborations in Schrödinger, Inc. fit the Dogs box because partner exit cuts off future milestone and royalty upside, so the program’s remaining value drops fast. These projects usually have near-zero share of the partner’s pipeline and little path to expand, making them better wind-down or divestiture candidates. In 2025, Schrödinger still depended on collaboration revenue, so losing a program can remove an entire future cash stream.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-priority internal discovery projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc.'s low-priority internal discovery projects fit the Dog box because they are still preclinical and do not show clear path-to-clinic value. That means they can absorb scientist time and compute spend without near-term commercial pull. In BCG terms, weak growth and weak share make them a capital drain, not a value engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core legacy R and D assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s non-core legacy R and D assets fit the Dogs box because older programs no longer align with its software-first platform and usually carry low success odds and little external demand. In FY2024, Research and Development expense was $239.7 million, so management’s rational move is to keep spend tight and redirect capital to higher-fit discovery tools and partnered programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak strategic fit\u003c\/li\u003e\n\u003cli\u003eLow success probability\u003c\/li\u003e\n\u003cli\u003eLimited outside buyer interest\u003c\/li\u003e\n\u003cli\u003eKeep funding near minimum\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall unpartnered pipeline remnants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall unpartnered pipeline remnants at Schrödinger, Inc. fit the Dogs box because they lack partner backing, so they draw little external capital and stay low on visibility. In 2025\/2026 terms, that means low share and weak growth odds unless a lead asset proves enough data to pull in a deal or milestone funding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow partner validation\u003c\/li\u003e\n\u003cli\u003eWeak funding support\u003c\/li\u003e\n\u003cli\u003eStranded, low-growth assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSchrödinger’s Dogs Drain Cash Without Meaningful Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s Dogs are discontinued, unpartnered, or legacy R\u0026amp;D assets with weak growth and near-zero market share. They do not create recurring revenue, and FY2025 still showed heavy dependence on collaboration cash, so these programs mainly consume capital while offering little upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset type\u003c\/th\u003e\n\u003cth\u003eKey signal\u003c\/th\u003e\n\u003cth\u003e2025 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscontinued drugs\u003c\/td\u003e\n\u003ctd\u003e0 marketed drugs\u003c\/td\u003e\n\u003ctd\u003eNo sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eFY2024 R\u0026amp;D $239.7m\u003c\/td\u003e\n\u003ctd\u003eCapital drain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Discovery segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s Drug Discovery segment is built on 1 thing: internal pipeline assets, not recurring software fees. In 2025, that left it with limited market share but high upside if even 1 program reaches approval. That mix is classic question mark territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSGR-1505\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGR-1505 fits the Question Mark quadrant: it is a clinical-stage oncology asset with high upside but no established market share yet. Its value depends on clinical success, while development risk remains high, since it has not reached commercialization. In Schrödinger, Inc.’s pipeline, it is a small current contributor but could become material if trials de-risk the program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSGR-2921\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGR-2921 sits in Schrödinger, Inc.’s question-mark bucket because it is still clinical-stage and has not yet proved it can turn science into sales. If its efficacy and safety data hold up, it could gain real value; if not, it stays a cash-consuming pipeline bet. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSGR-3515\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSGR-3515 is a newer internal oncology asset, so it fits Schrödinger, Inc.’s \"question mark\" bucket: high-growth potential, but still low share and early proof. Its value will hinge on clinical readouts and partner demand. Schrödinger ended 2024 with $1.0 billion in cash, giving it room to fund this risk, but SGR-3515 itself has no disclosed 2025\/2026 revenue yet.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage oncology asset\u003c\/li\u003e\n\u003cli\u003eLow share, high upside\u003c\/li\u003e\n\u003cli\u003eDepends on data and partners\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePreclinical pipeline candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s preclinical pipeline candidates are classic Question Marks: they sit at the front edge of the drug-development curve, so the upside is big, but the odds are still thin. Industry data show only about 10% of programs that enter Phase 1 ever win approval, so these assets need steady R\u0026amp;D spend before they can turn into Stars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh upside, low proof\u003c\/li\u003e\n\u003cli\u003eHeavy spend, uncertain return\u003c\/li\u003e\n\u003cli\u003eOnly clinic success unlocks value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSchrödinger’s Oncology Bets: High Risk, Big Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSchrödinger, Inc.’s Question Marks are early oncology assets with low current share and high trial risk, but big upside if data improve. They still burn R\u0026amp;D cash, while 2025 revenue stays tied to software and milestones, not these programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGR-1505\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eClinical-stage, no sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGR-2921\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eEarly proof, high risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGR-3515\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003ePrecommercial upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234935382281,"sku":"sdgr-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sdgr-bcg-matrix.webp?v=1785731091","url":"https:\/\/dcfanalyst.com\/products\/sdgr-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}